Ascendis Pharma‘s TransCon PTH can safely treat hypoparathyroidism, reducing the need for other therapies and improving…
Articles by Marisa Wexler, MS
TransCon PTH, an investigational therapy being developed by Ascendis Pharma, safely normalized calcium and phosphate levels,…
A novel approach for the production of parathyroid-like cells from stem cells — cells from which all others with…
ProLynx has been awarded a small business innovation research grant from the National Institutes of Health (NIH)…
Alizé Pharma 3 is rebranding as Amolyt Pharma and plans to start clinical testing of a potential hypoparathyroidism…
People with hypoparathyroidism may be at risk of having calcium crystals form in their tendons — a condition called…
People needing to take vitamin D and calcium supplements due to very low levels soon after thyroid cancer surgery are…
People with hypoparathyroidism after surgical removal of the thyroid may develop calcium-alkali syndrome (CAS) — particularly if they…
Lower levels of parathyroid hormone (PTH) in people with hypoparathyroidism may lead to decreased bone material strength and increase…
A Phase 2 trial testing the experimental therapy TransCon PTH in adults with hypoparathyroidism is expanding to allow for…